vs
EXACT SCIENCES CORP（EXAS）与Tyler Technologies（TYL）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Tyler Technologies的1.4倍（$878.4M vs $613.5M），Tyler Technologies净利率更高（13.2% vs -9.8%，领先23.0%），EXACT SCIENCES CORP同比增速更快（23.1% vs 8.6%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $2.0M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 6.5%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Tyler Technologies, Inc.是总部位于美国得克萨斯州普莱诺的科技企业，主营面向美国公共部门提供自研专有软件，目前在全美17个州设有办事处，另在加拿大安大略省多伦多市设有一处办公网点。
EXAS vs TYL — 直观对比
营收规模更大
EXAS
是对方的1.4倍
$613.5M
营收增速更快
EXAS
高出14.6%
8.6%
净利率更高
TYL
高出23.0%
-9.8%
自由现金流更多
EXAS
多$118.4M
$2.0M
两年增速更快
EXAS
近两年复合增速
6.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $613.5M |
| 净利润 | $-86.0M | $81.2M |
| 毛利率 | 70.1% | 48.3% |
| 营业利润率 | -9.4% | 16.3% |
| 净利率 | -9.8% | 13.2% |
| 营收同比 | 23.1% | 8.6% |
| 净利润同比 | 90.1% | — |
| 每股收益（稀释后） | $-0.45 | $1.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASTYL
| Q1 26 | — | $613.5M | ||
| Q4 25 | $878.4M | $575.2M | ||
| Q3 25 | $850.7M | $595.9M | ||
| Q2 25 | $811.1M | $596.1M | ||
| Q1 25 | $706.8M | $565.2M | ||
| Q4 24 | $713.4M | $541.1M | ||
| Q3 24 | $708.7M | $543.3M | ||
| Q2 24 | $699.3M | $541.0M |
净利润EXASTYL
| Q1 26 | — | $81.2M | ||
| Q4 25 | $-86.0M | $65.5M | ||
| Q3 25 | $-19.6M | $84.4M | ||
| Q2 25 | $-1.2M | $84.6M | ||
| Q1 25 | $-101.2M | $81.1M | ||
| Q4 24 | $-864.6M | $65.2M | ||
| Q3 24 | $-38.2M | $75.9M | ||
| Q2 24 | $-15.8M | $67.7M |
毛利率EXASTYL
| Q1 26 | — | 48.3% | ||
| Q4 25 | 70.1% | 45.5% | ||
| Q3 25 | 68.6% | 47.2% | ||
| Q2 25 | 69.3% | 45.8% | ||
| Q1 25 | 70.8% | 47.3% | ||
| Q4 24 | 69.0% | 43.8% | ||
| Q3 24 | 69.4% | 43.7% | ||
| Q2 24 | 69.8% | 44.0% |
营业利润率EXASTYL
| Q1 26 | — | 16.3% | ||
| Q4 25 | -9.4% | 13.0% | ||
| Q3 25 | -3.0% | 16.4% | ||
| Q2 25 | -0.3% | 16.0% | ||
| Q1 25 | -13.6% | 15.8% | ||
| Q4 24 | -122.8% | 13.2% | ||
| Q3 24 | -5.6% | 15.2% | ||
| Q2 24 | -3.8% | 14.4% |
净利率EXASTYL
| Q1 26 | — | 13.2% | ||
| Q4 25 | -9.8% | 11.4% | ||
| Q3 25 | -2.3% | 14.2% | ||
| Q2 25 | -0.1% | 14.2% | ||
| Q1 25 | -14.3% | 14.3% | ||
| Q4 24 | -121.2% | 12.1% | ||
| Q3 24 | -5.4% | 14.0% | ||
| Q2 24 | -2.3% | 12.5% |
每股收益（稀释后）EXASTYL
| Q1 26 | — | $1.88 | ||
| Q4 25 | $-0.45 | $1.50 | ||
| Q3 25 | $-0.10 | $1.93 | ||
| Q2 25 | $-0.01 | $1.93 | ||
| Q1 25 | $-0.54 | $1.84 | ||
| Q4 24 | $-4.69 | $1.48 | ||
| Q3 24 | $-0.21 | $1.74 | ||
| Q2 24 | $-0.09 | $1.57 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $346.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $3.6B |
| 总资产 | $5.9B | $4.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASTYL
| Q1 26 | — | $346.4M | ||
| Q4 25 | $964.7M | $1.1B | ||
| Q3 25 | $1.0B | $950.8M | ||
| Q2 25 | $858.4M | $892.3M | ||
| Q1 25 | $786.2M | $807.4M | ||
| Q4 24 | $1.0B | $768.0M | ||
| Q3 24 | $1.0B | $544.3M | ||
| Q2 24 | $946.8M | $258.0M |
总债务EXASTYL
| Q1 26 | — | — | ||
| Q4 25 | — | $599.7M | ||
| Q3 25 | — | $599.2M | ||
| Q2 25 | — | $598.8M | ||
| Q1 25 | — | $598.4M | ||
| Q4 24 | — | $597.9M | ||
| Q3 24 | — | $597.5M | ||
| Q2 24 | — | $597.1M |
股东权益EXASTYL
| Q1 26 | — | $3.6B | ||
| Q4 25 | $2.4B | $3.7B | ||
| Q3 25 | $2.5B | $3.6B | ||
| Q2 25 | $2.5B | $3.6B | ||
| Q1 25 | $2.4B | $3.5B | ||
| Q4 24 | $2.4B | $3.4B | ||
| Q3 24 | $3.2B | $3.3B | ||
| Q2 24 | $3.2B | $3.1B |
总资产EXASTYL
| Q1 26 | — | $4.8B | ||
| Q4 25 | $5.9B | $5.6B | ||
| Q3 25 | $5.9B | $5.5B | ||
| Q2 25 | $5.8B | $5.4B | ||
| Q1 25 | $5.7B | $5.2B | ||
| Q4 24 | $5.9B | $5.2B | ||
| Q3 24 | $6.7B | $5.0B | ||
| Q2 24 | $6.7B | $4.8B |
负债/权益比EXASTYL
| Q1 26 | — | — | ||
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 0.16× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $107.3M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $2.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 0.3% |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 1.32× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $585.7M |
8季度趋势，按日历期对齐
经营现金流EXASTYL
| Q1 26 | — | $107.3M | ||
| Q4 25 | $151.7M | $243.9M | ||
| Q3 25 | $219.9M | $255.2M | ||
| Q2 25 | $89.0M | $98.3M | ||
| Q1 25 | $30.8M | $56.2M | ||
| Q4 24 | $47.1M | $224.8M | ||
| Q3 24 | $138.7M | $263.7M | ||
| Q2 24 | $107.1M | $64.3M |
自由现金流EXASTYL
| Q1 26 | — | $2.0M | ||
| Q4 25 | $120.4M | $239.6M | ||
| Q3 25 | $190.0M | $251.3M | ||
| Q2 25 | $46.7M | $92.8M | ||
| Q1 25 | $-365.0K | $53.8M | ||
| Q4 24 | $10.7M | $221.0M | ||
| Q3 24 | $112.6M | $260.8M | ||
| Q2 24 | $71.2M | $57.7M |
自由现金流率EXASTYL
| Q1 26 | — | 0.3% | ||
| Q4 25 | 13.7% | 41.7% | ||
| Q3 25 | 22.3% | 42.2% | ||
| Q2 25 | 5.8% | 15.6% | ||
| Q1 25 | -0.1% | 9.5% | ||
| Q4 24 | 1.5% | 40.8% | ||
| Q3 24 | 15.9% | 48.0% | ||
| Q2 24 | 10.2% | 10.7% |
资本支出强度EXASTYL
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 0.8% | ||
| Q3 25 | 3.5% | 0.7% | ||
| Q2 25 | 5.2% | 0.9% | ||
| Q1 25 | 4.4% | 0.4% | ||
| Q4 24 | 5.1% | 0.7% | ||
| Q3 24 | 3.7% | 0.5% | ||
| Q2 24 | 5.1% | 1.2% |
现金转化率EXASTYL
| Q1 26 | — | 1.32× | ||
| Q4 25 | — | 3.72× | ||
| Q3 25 | — | 3.02× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | 0.69× | ||
| Q4 24 | — | 3.45× | ||
| Q3 24 | — | 3.47× | ||
| Q2 24 | — | 0.95× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
TYL
| Subscriptions | $429.7M | 70% |
| Maintenance | $108.9M | 18% |
| Other | $74.9M | 12% |
